FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995936706> ?p ?o ?g. }

• W1995936706 endingPage "948" @default.
• W1995936706 startingPage "940" @default.
• W1995936706 abstract "Background Alopecia areata (AA) is a relatively common inflammatory form of nonscarring hair loss of unknown pathogenesis, but possibly of autoimmune origin. Topical immunotherapy, using a potent contact allergen such as diphencyprone (DPC), is currently considered the most effective mode of treatment. However, the way in which DPC operates on hair follicles in AA still remains to be elucidated. Vascular endothelial growth factor (VEGF), essential for angiogenesis and vascular permeability, may be responsible for maintaining proper vasculature around hair follicles, and several studies provide evidence that apoptosis is a central element in the regulation of hair follicle and vascular regression. The cutaneous lymphocyte-associated antigen (CLA) and the skin-associated chemokine CCL27 highlight an important role for epithelial cells in controlling homeostatic lymphocyte trafficking. Objectives To determine the expression pattern of VEGF, factor (F)VIII, survivin, p16, CD4, CD8, CLA and CCL27 in alopecic skin before and after treatment with DPC. Methods Immunohistochemical staining methods were applied to skin biopsy specimens obtained from alopecic areas of 14 patients before and after DPC treatment and from five healthy subjects. Sections were incubated with monoclonal antibodies against VEGF, FVIII, survivin, p16, CCL27, CLA, CD4 and CD8, and their immunohistochemical expression was evaluated by light microscopy. Results The intensity of VEGF staining in alopecic human hair follicles was significantly lower than in healthy scalp tissue. FVIII immunostaining showed a significantly reduced development of the microvasculature in AA in comparison with healthy scalp tissue. After DPC therapy, cells of alopecic hair follicles showed a significant increase of VEGF immunopositivity, and the number of capillary vessels expressing FVIII was markedly increased in comparison with untreated scalp tissue. The increase in microvessels was associated with strong survivin expression in endothelial cells after treatment. All alopecic specimens showed expression of p16 in the hair follicle outer root sheath (ORS), with a significant increase after therapy. After treatment we observed a significantly decreased number of CD4+ cells and an increase of CD8+ cells (CD4/CD8 ratio 0·85) in alopecic skin compared with untreated scalp tissue (CD4/CD8 ratio 3·45). Most of the T lymphocytes found in inflammatory skin lesions expressed CLA antigen and after therapy we observed a significantly higher CLA positivity in hair follicles (50% or more) in comparison with untreated alopecic scalp tissue. Alopecic patients showed a CCL27 immunopositivity significantly lower than in normal scalp tissue. After DPC therapy the labelling intensity for CCL27 showed a significant increase both in the ORS and in the inner root sheath; similarly, in the basal interfollicular keratinocytes we observed a moderate increase in CCL27 expression. Conclusions Topical immunotherapy exerts an important role in angiogenesis, upregulating VEGF in human hair follicle keratinocytes and upregulating survivin to preserve endothelial cell viability. Moreover, it considerably alters the peribulbar CD4/CD8 ratio, restoring a condition close to normal scalp skin. Our study could contribute to explaining some aspects of AA pathogenesis that are still unknown and aid understanding of how DPC could act in this complex disease." @default.
• W1995936706 created "2016-06-24" @default.
• W1995936706 creator A5007186416 @default.
• W1995936706 creator A5023596882 @default.
• W1995936706 creator A5025788427 @default.
• W1995936706 creator A5034893882 @default.
• W1995936706 creator A5055586778 @default.
• W1995936706 creator A5058146894 @default.
• W1995936706 date "2004-05-01" @default.
• W1995936706 modified "2023-10-03" @default.
• W1995936706 title "Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study" @default.
• W1995936706 cites W1494254017 @default.
• W1995936706 cites W1568698910 @default.
• W1995936706 cites W1853022482 @default.
• W1995936706 cites W1969615847 @default.
• W1995936706 cites W1971782797 @default.
• W1995936706 cites W1974060291 @default.
• W1995936706 cites W1983601075 @default.
• W1995936706 cites W1984107812 @default.
• W1995936706 cites W1984156158 @default.
• W1995936706 cites W1993612200 @default.
• W1995936706 cites W2004017845 @default.
• W1995936706 cites W2007453680 @default.
• W1995936706 cites W2007653648 @default.
• W1995936706 cites W2011733119 @default.
• W1995936706 cites W2012525364 @default.
• W1995936706 cites W2014588982 @default.
• W1995936706 cites W2015358229 @default.
• W1995936706 cites W2017483812 @default.
• W1995936706 cites W2026393226 @default.
• W1995936706 cites W2030221255 @default.
• W1995936706 cites W2037548712 @default.
• W1995936706 cites W2039791984 @default.
• W1995936706 cites W2042690168 @default.
• W1995936706 cites W2049239235 @default.
• W1995936706 cites W2053900723 @default.
• W1995936706 cites W2062417507 @default.
• W1995936706 cites W2064681773 @default.
• W1995936706 cites W2066441074 @default.
• W1995936706 cites W2067519155 @default.
• W1995936706 cites W2072337591 @default.
• W1995936706 cites W2079732145 @default.
• W1995936706 cites W2082816999 @default.
• W1995936706 cites W2083540484 @default.
• W1995936706 cites W2093287401 @default.
• W1995936706 cites W2114962227 @default.
• W1995936706 cites W2156881992 @default.
• W1995936706 cites W2167490100 @default.
• W1995936706 cites W2191654227 @default.
• W1995936706 cites W4214683291 @default.
• W1995936706 cites W4232966924 @default.
• W1995936706 cites W4240889591 @default.
• W1995936706 cites W4248345836 @default.
• W1995936706 cites W95220500 @default.
• W1995936706 cites W2070132952 @default.
• W1995936706 doi "https://doi.org/10.1111/j.1365-2133.2004.05881.x" @default.
• W1995936706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15149507" @default.
• W1995936706 hasPublicationYear "2004" @default.
• W1995936706 type Work @default.
• W1995936706 sameAs 1995936706 @default.
• W1995936706 citedByCount "48" @default.
• W1995936706 countsByYear W19959367062012 @default.
• W1995936706 countsByYear W19959367062013 @default.
• W1995936706 countsByYear W19959367062014 @default.
• W1995936706 countsByYear W19959367062015 @default.
• W1995936706 countsByYear W19959367062016 @default.
• W1995936706 countsByYear W19959367062018 @default.
• W1995936706 countsByYear W19959367062019 @default.
• W1995936706 countsByYear W19959367062020 @default.
• W1995936706 countsByYear W19959367062021 @default.
• W1995936706 countsByYear W19959367062022 @default.
• W1995936706 crossrefType "journal-article" @default.
• W1995936706 hasAuthorship W1995936706A5007186416 @default.
• W1995936706 hasAuthorship W1995936706A5023596882 @default.
• W1995936706 hasAuthorship W1995936706A5025788427 @default.
• W1995936706 hasAuthorship W1995936706A5034893882 @default.
• W1995936706 hasAuthorship W1995936706A5055586778 @default.
• W1995936706 hasAuthorship W1995936706A5058146894 @default.
• W1995936706 hasConcept C121608353 @default.
• W1995936706 hasConcept C126322002 @default.
• W1995936706 hasConcept C142724271 @default.
• W1995936706 hasConcept C16005928 @default.
• W1995936706 hasConcept C167734588 @default.
• W1995936706 hasConcept C203014093 @default.
• W1995936706 hasConcept C204232928 @default.
• W1995936706 hasConcept C2775975398 @default.
• W1995936706 hasConcept C2776360568 @default.
• W1995936706 hasConcept C2777025900 @default.
• W1995936706 hasConcept C2777216303 @default.
• W1995936706 hasConcept C2777524370 @default.
• W1995936706 hasConcept C2780394083 @default.
• W1995936706 hasConcept C71924100 @default.
• W1995936706 hasConcept C86803240 @default.
• W1995936706 hasConceptScore W1995936706C121608353 @default.
• W1995936706 hasConceptScore W1995936706C126322002 @default.
• W1995936706 hasConceptScore W1995936706C142724271 @default.
• W1995936706 hasConceptScore W1995936706C16005928 @default.
• W1995936706 hasConceptScore W1995936706C167734588 @default.

• next